SCHEMBL65663

SCHEMBL65663

O=C(COc1ccc(F)c(Cl)c1)N1CCC(S(=O)(=O)Nc2ccccc2)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
MAPT P10636 5/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
GAA P10253 3/20 0.46
RAB9A P51151 2/20 0.46
L3MBTL1 Q9Y468 4/20 0.45
TDP1 Q9NUW8 1/20 0.44
PKM P14618 2/20 0.44
CPT2 P23786 1/20 0.44
CPT1A P50416 1/20 0.44
CPT1B Q92523 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ATF4 P18848 2/20 0.43
KMT2A Q03164 3/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
MEN1 O00255 2/20 0.42
POLB P06746 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL66545 0.94 ALDH1A1 (0.48) ALDH1A1MAPTSMN1; SMN2GAARAB9A
SCHEMBL57050 0.87 KMT2A (0.47) ALDH1A1MAPTSMN1; SMN2GAARAB9A
SCHEMBL8243715 0.84 SMN1; SMN2 (0.41) ALDH1A1MAPTSMN1; SMN2GAARAB9A
SCHEMBL8236980 0.83 ALDH1A1 (0.51) ALDH1A1MAPTSMN1; SMN2GAARAB9A
SCHEMBL66069 0.82 TDP1 (0.47) ALDH1A1MAPTSMN1; SMN2GAARAB9A
SCHEMBL56987 0.81 KMT2A (0.51) ALDH1A1SMN1; SMN2GAAL3MBTL1PKM
SCHEMBL56480 0.81 SMN1; SMN2 (0.53) ALDH1A1MAPTSMN1; SMN2RAB9AL3MBTL1
SCHEMBL8243869 0.77 SMN1; SMN2 (0.43) ALDH1A1MAPTSMN1; SMN2RAB9AL3MBTL1
SCHEMBL65760 0.77 SMN1; SMN2 (0.50) ALDH1A1MAPTSMN1; SMN2RAB9AL3MBTL1
SCHEMBL90762 0.70 GPR183 (0.52) ALDH1A1SMN1; SMN2GAARAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129546-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 US disclosed
US-8129546-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 US disclosed
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-31 US disclosed
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-31 US disclosed
US-7842819-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-30 US disclosed
US-7842819-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-30 US disclosed
US-20070203122-A1 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-08-30 US disclosed
US-20070203122-A1 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203122-A1 Derivatives for modulation of ion channels TRPV1, TRPA1, TRPV2 ALDH1A1 3010/4885MAPT 2230/4885SMN1; SMN2 672/4885
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS TRPV1, TRPA1, TRPV2 ALDH1A1 3010/4885MAPT 2230/4885SMN1; SMN2 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.